Pfizer celebrated the first phase of our state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina, andannounced an additional investment of $500 million for facility expansion.

Sanford – one of Pfizer’s largest biotech manufacturing sites globally – is a clinical and commercial manufacturer of vaccine intermediates/drug substances and gene therapy drug substances/drug products.

This new gene therapy facility is expected to develop novel methods to deliver transformative treatments to patients. Gene therapies represent potential cures for debilitating and often fatal genetic diseases.

​“These investments provide additionalcapability and capacity for our growing gene therapy pipeline,” says Tony Mulcahy, Sanford Site Leader. “Our colleagues are inspired by the opportunity we have to help patients.”